JILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2025.
Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2025 was a year of resilience for Zhengye. While the broader hog market experienced low and volatile price fluctuations and government macro-control policies contributed to near-term pressure on swine vaccine demand, we remained focused on executing our strategy and driving long-term value creation. We are encouraged by the continued growth in our other vaccines segment, particularly vaccines for sheep, which contributed to improving our revenue mix. On the international front, we made progress in advancing vaccine registrations in certain overseas markets, including Egypt, Pakistan, and Vietnam, supporting our long-term expansion strategy."
"We continued to prioritize research and development as a core driver of our future growth. In 2025, we achieved several regulatory milestones, including the approval of two National Category I New Veterinary Drugs and one National Category III New Veterinary Drug from the Ministry of Agriculture and Rural Affairs. We also secured new product approvals across multiple animal species, including swine, poultry, cattle, and sheep, further broadening our commercial offerings. We believe these achievements reflect our ongoing innovation efforts and support our long-term growth strategy."
Mr. Aiden Han, co-chief executive officer of Zhengye, added, "With our Nasdaq listing, we further strengthened our capital base and financial position, providing a foundation to support our strategic priorities. We ended the year with a stronger cash position of RMB50.3 million, representing an increase from the prior year, which is expected to enhance our ability to invest in research and development, expand our product portfolio, and support future growth initiatives."
"Looking ahead, we are encouraged by early signs of a gradual recovery in China's swine market, with industry expectations pointing to a potential price inflection point around mid-year in 2026. We aim to deepen strategic customer engagement, strengthen our product portfolio, expand our customer service ecosystem, and selectively pursue opportunities in the companion animal sector as a new growth driver. We believe these initiatives, together with our operational foundation, will support our ability to navigate industry cycles. We are grateful for the support of our shareholders, customers, and partners, and remain committed to building on our progress as we navigate this period and lay a foundation for Zhengye's long-term growth."
Fiscal Year 2025 Financial Summary
-- Net revenue was RMB116.4 million (US$16.6 million) in the fiscal year
ended December 31, 2025, compared to RMB186.4 million in the fiscal year
ended December 31, 2024.
-- Gross profit was RMB23.9 million (US$3.4 million) in the fiscal year
ended December 31, 2025, compared to RMB91.3 million in the fiscal year
ended December 31, 2024.
-- Gross profit margin was 20.5% in the fiscal year ended December 31, 2025,
compared to 49.0% in the fiscal year ended December 31, 2024.
-- Total operating expenses were RMB94.4 million (US$13.5 million) in the
fiscal year ended December 31, 2025, compared to RMB74.9 million in the
fiscal year ended December 31, 2024.
-- Net loss was RMB83.0 million (US$11.9 million) in the fiscal year ended
December 31, 2025, compared to net income of RMB13.5 million in the
fiscal year ended December 31, 2024.
-- Basic and diluted loss per share was RMB1.47 (US$0.21) in the fiscal year
ended December 31, 2025, compared to basic and diluted earnings per share
of RMB0.25 in the fiscal year ended December 31, 2024.
Fiscal Year 2025 Financial Results
Net Revenue
Net revenue was RMB116.4 million (US$16.6 million) in the fiscal year ended December 31, 2025, representing a decrease of 37.6% from RMB186.4 million in the fiscal year ended December 31, 2024.
For the years ended December 31,
-----------------------------------------
2024 2025
---------------- -----------------------
(in thousands, except for percentages)
Revenue RMB % RMB US$ %
--------- ----- -------- ------- ----
Swine vaccines 157,789 84.7 90,143 12,890 77.5
Poultry vaccines 15,506 8.3 12,480 1,785 10.7
Other vaccines 13,061 7.0 13,739 1,964 11.8
--------- ----- -------- ------- ----
Total revenue 186,356 100 116,362 16,639 100
========= ===== ======== ======= ====
-- Revenue from sales of swine vaccines was RMB90.1 million (US$12.9
million) in the fiscal year ended December 31, 2025, decreased from
RMB157.8 million in the fiscal year ended December 31, 2024. This
decrease was primarily driven by a downturn in the hog market in 2025,
characterized by low and volatile prices. Additionally, government
macro-control policies aimed at reducing the inventory of productive sows
to alleviate periodic oversupply contributed to the reduced demand for
swine vaccines.
-- Revenue from sales of poultry vaccines was RMB12.5 million (US$1.8
million) in the fiscal year ended December 31, 2025, decreased from
RMB15.5 million in the fiscal year ended December 31, 2024. The decrease
was primarily due to normal market fluctuations.
-- Revenue from sales of other vaccines was RMB13.7 million (US$2.0 million)
in the fiscal year ended December 31, 2025, increased from RMB13.1
million in the fiscal year ended December 31, 2024. The increase in sales
of other vaccines was caused by the increased sales of the vaccines for
sheep.
Cost of Revenue
Cost of revenue was RMB92.5 million (US$13.2 million) in the fiscal year ended December 31, 2025, representing a decrease of 2.7% from RMB95.1 million in the fiscal year ended December 31, 2024. The decrease was mainly due to the decrease in the cost of swine vaccines.
Gross Profit
Gross profit was RMB23.9 million (US$3.4 million) in the fiscal year ended December 31, 2025, decreased from RMB91.3 million in the fiscal year ended December 31, 2024.
Gross profit margin was 20.5% in the fiscal year ended December 31, 2025, decreased from 49.0% in the fiscal year ended December 31, 2024, mainly due to the lower sales price and unchanged fixed cost.
Operating Expenses
Total operating expenses were RMB94.4 million (US$13.5 million) in the fiscal year ended December 31, 2025, increased from RMB74.9 million in the fiscal year ended December 31, 2024.
-- Sales and marketing expenses were RMB43.9 million (US$6.3 million) in the
fiscal year ended December 31, 2025, increased from RMB41.3 million in
the fiscal year ended December 31, 2024. The increase in sales and
marketing expenses was primarily due to higher payroll for sales staffs,
and increased advertising expenses and entertainment, partially offset by
a decrease in marketing promotion expenses.
-- General and administrative expenses were RMB31.0 million (US$4.4 million)
in the fiscal year ended December 31, 2025, increased from RMB22.6
million in the fiscal year ended December 31, 2024. The increase in
general and administrative expenses was attributed to the increase in
professional technical services and in depreciation and amortization.
-- Research and development expenses were RMB18.0 million (US$2.6 million)
in the fiscal year ended December 31, 2025, increased from RMB12.8
million in the fiscal year ended December 31, 2024. The increase in
research and development expenses mainly resulted from an increase in
research and development projects, which led to an increase in materials.
Net Income (Loss)
Net loss was RMB83.0 million (US$11.9 million) in the fiscal year ended December 31, 2025, compared to net income of RMB13.5 million in the fiscal year ended December 31, 2024.
Basic and Diluted Earnings (Loss) per Share
Basic and diluted loss per share was RMB1.47 (US$0.21) in the fiscal year ended December 31, 2025, compared to basic and diluted earnings per share of RMB0.25 in the fiscal year ended December 31, 2024.
Financial Condition
As of December 31, 2025, the Company had cash of RMB50.3 million (US$7.2 million), compared to RMB18.6 million as of December 31, 2024.
Net cash provided by operating activities was RMB13.3 million (US$1.9 million) in the fiscal year ended December 31, 2025, compared to RMB41.0 million in the fiscal year ended December 31, 2024.
Net cash used in investing activities was RMB12.6 million (US$1.8 million) in the fiscal year ended December 31, 2025, compared to RMB27.7 million in the fiscal year ended December 31, 2024.
Net cash provided by financing activities was RMB32.3 million (US$4.6 million) in the fiscal year ended December 31, 2025, compared to net cash used in financing activities of RMB22.1 million in the fiscal year ended December 31, 2024.
Exchange Rate Information
This announcement contains translations of certain foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations of Renminbi ("RMB") into U.S. dollars ("US$") were made at RMB6.9931 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Federal Reserve Board on December 31, 2025.
About Zhengye Biotechnology Holding Limited
Through Jilin Zhengye Biological Products Co., Ltd., the Company's operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity's products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt as of the date of this press release. The operating entity has three GMP veterinary vaccine production floors (including 13 GMP vaccine production lines), one quality examination center, and one animal facility for vaccine development. The operating entity has 49 employees who have over a decade of tenure and experience in the veterinary vaccine industry. For more information, please visit the Company's website: http://ir.jlzybio.com.
Forward-Looking Statements
This announcement contains statements that may constitute "forward-looking" statements which are made pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the United States Securities and Exchange Commission.
For more information, please contact:
Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of RMB and US$, except for number of
shares)
As of December 31,
---------------------------
2024 2025
-------- -----------------
RMB RMB US$
ASSETS
Current assets:
Cash 18,604 50,332 7,197
Restricted cash 2 2 -
Short-term investments 1,433 1,560 223
Notes receivable, net 25,592 - -
Accounts receivable, net 59,563 18,485 2,643
Advance to suppliers 10,788 2,208 316
Inventories, net 58,220 39,166 5,601
Prepayments and other current
assets, net 2,626 25,667 3,670
Other receivable-a related party 738 - -
------- -------- -------
Total current assets 177,566 137,420 19,650
------- -------- -------
Non-current assets:
Property, plant and equipment,
net 255,164 236,812 33,863
Land use rights, net 7,930 7,673 1,097
Intangible assets, net 14,850 47,084 6,732
Right-of-use assets, net - 469 67
Long-term prepayments 18,698 7,014 1,003
Deferred IPO expenses 8,048 - -
Net deferred tax assets 10,991 - -
------- -------- -------
Total non-current assets 315,681 299,052 42,762
------- -------- -------
Total assets 493,247 436,472 62,412
======= ======== =======
LIABILITIES AND SHAREHOLDERS'
EQUITY
Current liabilities:
Short-term loans 74,443 65,100 9,309
Current maturities of long-term
loans 7,190 700 100
Operating lease
liability-current - 106 15
Accounts payable 42,960 44,010 6,296
Contract liabilities 3,485 4,752 680
Taxes payable 2,066 2,345 335
Amount due to related parties 146 - -
Accrued expenses and other
liabilities 5,617 3,463 495
------- -------- -------
Total current liabilities 135,907 120,476 17,230
------- -------- -------
Non-current liabilities:
Long-term loans 4,800 8,850 1,266
Operating lease
liability-non-current - 327 47
Deferred tax liabilities - 104 15
------- -------- -------
Total non-current liabilities 4,800 9,281 1,328
------- -------- -------
Total liabilities 140,707 129,757 18,558
======= ======== =======
Commitments and contingencies
Shareholders' equity:
Class A ordinary shares
(US$0.000025 par value;
1,900,000,000 shares
authorized; 5,666,376 and
7,391,376 shares issued and
outstanding as of December
31, 2024 and 2025,
respectively)* 1 1 -
Class B ordinary shares
(US$0.000025 par value;
100,000,000 shares
authorized; 40,000,000 and
40,000,000shares issued and
outstanding as of December
31, 2024 and 2025,
respectively)* 7 7 1
Additional paid-in capital 203,150 240,752 34,427
Statutory reserves 32,647 32,647 4,668
Retained earnings (deficit) 48,151 (21,633) (3,099)
Accumulated other comprehensive
income 3 (1,926) (275)
------- -------- -------
Total Zhengye Biotechnology
Holding Limited's shareholders'
equity 283,959 249,848 35,722
------- -------- -------
Noncontrolling interests 68,581 56,867 8,132
------- -------- -------
Total equity 352,540 306,715 43,854
------- -------- -------
Total liabilities and equity 493,247 436,472 62,412
======= ======== =======
* As of December 31, 2025, share reclassification was
retroactively restated with effective date of March 24, 2026
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(LOSS)
(Amounts in thousands of RMB and US$, except for number of shares and
per share data)
For the years ended December 31,
-----------------------------------------------
2023 2024 2025
----------- ---------- ----------------------
RMB RMB RMB USD
Net revenues 211,651 186,356 116,362 16,639
Cost of revenues (94,143) (95,061) (92,493) (13,227)
---------- ---------- ---------- ----------
Gross profit 117,508 91,295 23,869 3,412
Sales and marketing
expenses (40,743) (41,269) (43,918) (6,280)
General and
administrative
expenses (23,592) (22,575) (31,006) (4,434)
Research and
development
expenses (11,901) (12,794) (18,013) (2,576)
Reversal of
(provision for)
credit losses 3,714 1,782 (1,438) (206)
---------- ---------- ---------- ----------
Total operating
expenses (72,522) (74,856) (94,375) (13,496)
---------- ---------- ---------- ----------
Operating income
(loss) 44,986 16,439 (70,506) (10,084)
Other income
(expenses):
Interest income 312 231 96 14
Interest expense (4,423) (4,043) (3,400) (486)
Unrealized gains on
short-term
investments - 209 127 18
Unrealized foreign
exchange gain
(loss) - 679 (312) (45)
Government subsidy 2,653 733 2,252 322
Other expenses
(income) 234 146 (130) (19)
---------- ---------- ---------- ----------
Total other
expenses, net (1,224) (2,045) (1,367) (196)
---------- ---------- ---------- ----------
Income (loss) before
income taxes 43,762 14,394 (71,873) (10,280)
Income tax expenses (6,253) (924) (11,095) (1,587)
---------- ---------- ---------- ----------
Net income (loss) 37,509 13,470 (82,968) (11,867)
Net (income) loss
attributable to
noncontrolling
interests (6,052) (2,159) 13,184 1,885
---------- ---------- ---------- ----------
Net income (loss)
attributable to the
Zhengye
Biotechnology
Holding Limited's
shareholders 31,457 11,311 (69,784) (9,982)
========== ========== ========== ==========
Comprehensive
income (loss)
Net income (loss) 37,509 13,470 (82,968) (11,867)
Other
comprehensive
income (loss)
Foreign currency
translation
adjustment - 3 (1,929) (275)
---------- ---------- ---------- ----------
Total comprehensive
income (loss) 37,509 13,473 (84,897) (12,142)
Total comprehensive
(income) loss
attributable to
non-controlling
interest (6,052) (2,159) 13,184 1,885
---------- ---------- ---------- ----------
Total comprehensive
income (loss)
attributable to
the Zhengye
Biotechnology
Holding Limited's
shareholders 31,457 11,314 (71,713) (10,257)
========== ========== ========== ==========
Earnings (loss)
per share:
-Basic and diluted
-- Class A Ordinary
shares 0.69 0.25 (1.47) (0.21)
-Basic and diluted
-- Class B Ordinary
shares 0.69 0.25 (1.47) (0.21)
Weighted average
shares outstanding
used in
calculating
basic and diluted
earnings per
share:
Ordinary
shares -- basic and
diluted 45,666,376 45,666,376 47,349,869 47,349,869
Basic and diluted --
Class A Ordinary
shares* 5,666,376 5,666,376 7,349,869 7,349,869
Basic and diluted --
Class B Ordinary
shares* 40,000,000 40,000,000 40,000,000 40,000,000
* As of December 31, 2025, share reclassification was retroactively
restated with effective date of March 24, 2026.
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of RMB and US$, except for number of shares)
For the years ended December 31,
---------------------------------------
2023 2024 2025
--------- -------- ------------------
RMB RMB RMB US$
CASH FLOWS FROM
OPERATING ACTIVITIES
Net income (loss) 37,509 13,470 (82,968) (11,867)
Adjustments to reconcile
net income (loss) to net
cash provided by
operating activities:
Depreciation and
amortization 23,912 24,163 25,883 3,702
Amortization of operating
lease right-of-use
assets - - 72 10
Provision for (reversal
of) credit losses (3,714) (1,782) 1,438 206
Impairment for inventory 10,026 5,962 12,801 1,831
Loss on disposal of
property and equipment 187 174 - -
Deferred tax expenses 541 924 11,095 1,587
Unrealized gains on
short-term investments - (209) (127) (18)
Unrealized foreign
exchange (gain) loss - (679) 312 45
Changes in operating
assets and liabilities:
Notes receivable 8,310 (3,752) 20,962 2,998
Accounts receivable 31,044 16,345 39,709 5,678
Advance to suppliers (619) (7,677) 1,979 283
Inventories (12,902) (5,882) 6,252 894
Prepayments and other
current assets (563) (1,283) (23,306) (3,333)
Other receivable-a related
party (738) - 738 106
Operating leases
liabilities - - (108) (15)
Accounts payable (35,613) (404) (3,362) (478)
Taxes payable (7,702) (229) 279 40
Contract liabilities (715) (400) 1,267 182
Accrued expense and other
liabilities (582) 2,698 417 60
Other
payables -- non-current (197) (393) - -
-------- -------- -------- --------
Net cash provided by
operating activities 48,184 41,046 13,333 1,911
-------- -------- -------- --------
CASH FLOWS FROM
INVESTING ACTIVITIES
Loans to related party - - (7,000) (1,001)
Repayment of lending to
related party - - 7,000 1,001
Purchase of short-term
investments (1,224) - - -
Purchase of property,
plant and equipment (7,396) (13,587) (1,008) (144)
Prepayment for purchase of
intangible assets (4,204) (14,186) (11,622) (1,662)
Proceeds from disposal of
property, plant and
equipment 1,059 108 - -
-------- -------- -------- --------
Net cash used in investing
activities (11,765) (27,665) (12,630) (1,806)
-------- -------- -------- --------
CASH FLOWS FROM
FINANCING ACTIVITIES
Proceeds from loans 79,860 90,122 70,468 10,077
Repayment of loans (54,890) (92,860) (82,562) (11,806)
Repayment of related
parties - - (146) (20)
Proceeds from related
parties - 146 - -
Dividend payment to
shareholders (39,452) (16,023) - -
Deferred IPO expenses (4,497) (3,514) - -
Proceeds from initial
public offering - - 43,080 6,160
Shareholder contribution - - 1,470 210
-------- -------- -------- --------
Net cash provided by (used
in) financing activities (18,979) (22,129) 32,310 4,621
-------- -------- -------- --------
Effect of exchange rate
changes on cash - 168 (1,285) (190)
Net increase (decrease) in
cash and restricted cash 17,440 (8,580) 31,728 4,536
Cash and restricted cash
at beginning of year 9,746 27,186 18,606 2,661
-------- -------- -------- --------
Cash and restricted cash
at end of year 27,186 18,606 50,334 7,197
======== ======== ======== ========
SUPPLEMENTAL DISCLOSURE
OF CASH FLOW
INFORMATION:
Cash paid for:
Interest 4,423 3,985 3,356 480
======== ======== ======== ========
Income taxes 10,486 116 - -
======== ======== ======== ========
NON-CASH INVESTING AND
FINANCING ACTIVITIES:
Liabilities assumed in
connection with purchase
of property, plant and
equipment 2,345 8,633 1,101 157
======== ======== ======== ========
Liabilities assumed in
connection with purchase
of intangible asset - - 3,602 515
======== ======== ======== ========
Right of use assets
obtained in exchange for
operating lease
obligation - - 541 77
======== ======== ======== ========
Reclassification of IPO
expenses into additional
paid-in capital - - 8,663 1,239
======== ======== ======== ========
View original content:https://www.prnewswire.com/news-releases/zhengye-biotechnology-holding-limited-announces-fiscal-year-2025-financial-results-302756248.html
SOURCE Zhengye Biotechnology Holding Limited
(END) Dow Jones Newswires
April 28, 2026 16:30 ET (20:30 GMT)